
Please try another search
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Willard H. Dere | 71 | 2018 | Independent Director |
Misti Ushio | 54 | - | Board Observer |
Kristen M. Hege | 62 | 2016 | Independent Director |
Martin H. Huber | 64 | 2020 | President, CEO & Director |
David M. Mott | 60 | 2012 | Independent Chairman |
Lawrence M. Alleva | 76 | 2017 | Independent Director |
Anna Protopapas | 61 | 2015 | Director |
Howard A. Burris | - | - | Member of the Scientific Advisory Board |
Peter A. Kiener | 73 | - | Member of the Scientific Advisory Board |
Allene Maria Diaz | 61 | 2021 | Independent Director |
Andrew A. F. Hack | 51 | 2017 | Independent Director |
K. Dane Wittrup | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review